In this retrospective analysis of tumor samples from ERα-positive postmenopausal breast cancer patients, we have shown the clinical validity of p-p70S6K, as a marker of PI3K and/or MAPK pathway activation, to predict adjuvant tamoxifen resistance. This evidence concerns the gene ESR1 and breast cancer.